Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 5/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.38 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.38 |
| ▸ | TST | Q16762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991659 | 0.76 | MAPK1 (0.50) | DGKANLRP3MAPK1LPAR1 | |
| SCHEMBL14010258 | 0.76 | MAPK1 (0.50) | DGKANLRP3MAPK1LPAR1 | |
| SCHEMBL4991663 | 0.76 | MAPK1 (0.50) | DGKANLRP3MAPK1LPAR1 | |
| SCHEMBL4994061 | 0.76 | MAPK1 (0.50) | DGKANLRP3MAPK1LPAR1 | |
| SCHEMBL4994069 | 0.76 | MAPK1 (0.50) | DGKANLRP3MAPK1LPAR1 | |
| SCHEMBL14010283 | 0.76 | MAPK1 (0.50) | DGKANLRP3MAPK1LPAR1 | |
| SCHEMBL4996451 | 0.74 | MAPK1 (0.72) | MAPK1 | |
| SCHEMBL14010294 | 0.74 | MAPK1 (0.72) | MAPK1 | |
| SCHEMBL17318241 | 0.72 | TLR4 (0.51) | DGKANLRP3LPAR1 | |
| SCHEMBL6671603 | 0.71 | NLRP3 (0.53) | DGKANLRP3PRKCALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624190-B2 | Useful as biodegradable surfactants and in enzymatic processes using a chitinase (N-acetylglucosaminidase) | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2003-09-23 | — | — | US | disclosed |
| US-20020028954-A1 | 2-acylamino-2-deoxy-glucono-1,5-lactones, a method for the production thereof, compositions containing them, and uses thereof | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2002-03-07 | — | — | US | disclosed |
| EP-1131311-A1 | 2-ACYLAMINO-2-DEOXY-GLUCONO-1,5-LACTONES, METHOD FOR OBTAINING SAME, COMPOSITIONS COMPRISING THEM AND USES | UNIVERSITE PIERRE ET MARIE CURIE PARIS VI (FR) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031059-A1 | 2-ACYLAMINO-2-DEOXY-GLUCONO-1,5-LACTONES, METHOD FOR OBTAINING SAME, COMPOSITIONS COMPRISING THEM AND USES | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028954-A1 | 2-acylamino-2-deoxy-glucono-1,5-lactones, a method for the production thereof, compositions containing them, and uses thereof | ENGASE, FUT5, CHIT1 | DGKA 2170/4885NLRP3 4357/4885MAPK1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.